A Study of GR1803 in Systemic Lupus Erythematosus

NCT07348055 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erthematosus
Auto Immune Disease

Interventions

BIOLOGICAL: GR1803 injection

Sponsor

Genrix (Shanghai) Biopharmaceutical Co., Ltd.